Protective effect of nebivolol on doxorubicin-induced cardiotoxicity in rats

about

Protective effect of nebivolol on doxorubicin-induced cardiotoxicity in rats

Item

http://www.wikidata.org/entity/Q58588421

description

im Oktober 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2018

@uk

name

Protective effect of nebivolol on doxorubicin-induced cardiotoxicity in rats

@en

Protective effect of nebivolol on doxorubicin-induced cardiotoxicity in rats

@nl

type

Item

label

Protective effect of nebivolol on doxorubicin-induced cardiotoxicity in rats

@en

Protective effect of nebivolol on doxorubicin-induced cardiotoxicity in rats

@nl

prefLabel

Protective effect of nebivolol on doxorubicin-induced cardiotoxicity in rats

@en

Protective effect of nebivolol on doxorubicin-induced cardiotoxicity in rats

@nl

P1476

Protective effect of nebivolol on doxorubicin-induced cardiotoxicity in rats

@en

P2093

Enas Ahmed Mohamed

http://www.w3.org/2001/XMLSchema#string

Hussien H Kassem

http://www.w3.org/2001/XMLSchema#string

P2860

Doxorubicin cardiomyopathy

Doxorubicin-induced carbonylation and degradation of cardiac myosin binding protein C promote cardiotoxicity

Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis.

Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management.

Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro

Nebivolol: the somewhat-different beta-adrenergic receptor blocker.

Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies.

Nebivolol: vasodilator properties and evidence for relevance in treatment of cardiovascular disease.

Change in TNF-alpha receptor expression is a relevant event in doxorubicin-induced H9c2 cardiomyocyte cell death.

Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats.

P304

1450-1458

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5114/AOMS.2018.79008

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30393501

http://www.w3.org/2001/XMLSchema#string

P932

6209710

http://www.w3.org/2001/XMLSchema#string